Bone Biologics is a biotechnology startup founded in 2004 and headquartered in the United States. The company is a spin off of the Musculoskeletal Transplant Foundation (MTF) and focuses on the regenerative medicine orthobiologics space. Its proprietary platform technology UCB-1™, exclusively licensed from UCLA, has shown superior normal bone growth in large animal model studies.
With a mission to improve clinical outcomes and reduce healthcare costs associated with lumbar spinal fusion, Bone Biologics is developing a lead product for bone regeneration using recombinant human protein growth factor Nell-1. The company aims to address the current underserved quality outcomes in lumbar fusion and believes in the potential of new biological therapies.
In March 2024, Bone Biologics secured a $2.00M post-IPO equity investment. Notably, the company was acquired in 2006 by MTF, which has been the major shareholder and primary funder since the acquisition. With its focus on enhancing bone regeneration and repair, Bone Biologics is poised to make an impact in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $2.00M | - | 04 Mar 2024 | |
| Post-IPO Equity | $5.00M | - | 14 Jun 2023 | |
| Post-IPO Equity | $5.10M | - | 07 Oct 2022 | |
| Post-IPO Equity | $7.90M | - | 15 Oct 2021 | |
| Post-IPO Equity | $3.90M | - | 23 Jul 2018 |
We care about your data, and we'd love to use cookies make your experience better.
